Retail investors showed strong interest in YD Bio (NASDAQ:YDES) late Sunday after the biotech firm announced it had finalized its merger with Breeze Holdings Acquisition Corp, a special purpose acquisition company (SPAC).
YD Bio’s common shares and warrants started trading on the Nasdaq Global Market on Aug. 29 under the tickers YDES and YDESW, carrying forward the listing of Breeze Holdings Acquisition Corp. So far in 2025, the SPAC’s shares, now YDES, have risen 11.1%.
Breeze shareholders approved the merger at a meeting on Aug. 14. Alongside the deal, a private investment in public equity (PIPE) closed, and with cash from Breeze’s trust account, YD Bio anticipates securing over $11.5 million to support its operations.
Chairman and CEO Ethan Shen described the Nasdaq listing as “a milestone in the company’s transformation from a supplier of clinical trial drugs to a developer of diagnostics and therapies.”
YD Bio’s pipeline features DNA methylation-based cancer detection tests licensed from EG BioMed, including a lab-developed pancreatic cancer screening test already available via EG BioMed’s certified laboratory. A follow-up test for monitoring recurrent breast cancer is expected to launch later this year.
In ophthalmology, the company is advancing stem cell and exosome-based therapies in partnership with 3D Global Biotech to treat conditions such as dry eye syndrome, glaucoma, and corneal injury. Planned trials in 2027 aim to evaluate exosome-based contact lenses and artificial tears.
The company also provides investigational drugs and related materials to pharmaceutical firms worldwide, supporting clinical trials and post-launch commercialization. Multi-decade licensing agreements and proprietary patents offer what YD Bio calls a “significant first-mover” advantage in its target markets.
Legal counsel for YD Bio was provided by ArentFox Schiff LLP and Ogier, while I-Bankers Securities Inc. advised Breeze, with Woolery & Co. PLLC serving as its legal counsel.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.